Albireo to Participate in Guggenheim Nantucket Therapeutics Conference
BOSTON, Sept. 20, 2022 - Albireo Pharma, Inc. (Nasdaq: ALBO) announced its participation in the Guggenheim Therapeutics Conference in Nantucket, MA, from September 27-29, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BOSTON, Sept. 20, 2022 - Albireo Pharma, Inc. (Nasdaq: ALBO) announced its participation in the Guggenheim Therapeutics Conference in Nantucket, MA, from September 27-29, 2022. CEO Ron Cooper will present on September 28 at 8:30 AM ET. A replay of the webcast will be available on the Albireo Investors page.
Albireo focuses on developing bile acid modulators for treating liver diseases. Its lead product, Bylvay, is FDA-approved for pruritus in progressive familial intrahepatic cholestasis (PFIC) and is being studied for other liver diseases. In Europe, Bylvay is reimbursed for PFIC.
Details
News Market Reaction – ALBO
The recorded move for ALBO in the trading session of this news was +2.63%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the Guggenheim Therapeutics Conference in Nantucket, MA, from September 27-29, 2022. Ron Cooper, President and Chief Executive Officer of Albireo, will be presenting on September 28, 2022, at 8:30 AM ET.
A replay of the webcast will be available on-demand on the Albireo Investors page: ir.albireopharma.com.
About Albireo
Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and it is also being developed to treat other rare pediatric cholestatic liver diseases with Phase 3 trials in Alagille syndrome (ALGS) and biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. In Europe, Bylvay is reimbursed for the treatment of PFIC in Germany, England, Wales & Northern Ireland, Scotland, Italy, and Belgium. The Company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Media Contacts:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lance Buckley, 917-439-2241, lbuckley@lippetaylor.com
Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.